PRR22:前列腺癌的新预后指标和治疗目标
Wenxia Chen1, Guodong Ding2, Yuantang Zhong2
1Department of Oncology, Longgang District Central Hospital of Shenzhen, Shenzhen 518166, Guangdong Province, China.
Anti-cancer agents in medicinal chemistry
|October 1, 2025
概括
富含林的蛋白22 (PRR22) 在前列腺癌 (PRAD) 中过度表达,预示着不良结果和耐药性. 这种基因可能作为PRAD的新生物标志物和治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 前列腺癌 (PRAD) 缺乏足够的预后生物标志物和治疗点.
- 在PRAD中富含林蛋白编码基因PRR22的作用目前尚不确定.
研究的目的:
- 系统地调查PRR22在前列腺癌中的临床相关性和机制性影响.
主要方法:
- 在TCGA-PRAD和其他数据集中分析PRR22表达.
- 使用卡普兰-梅尔和考克斯分析进行预测评估.
- 通过GSEA进行机制性调查,免疫分析,MSI/mRNA-si相关性和药物敏感性分析.
主要成果:
- 在PRAD组织中,PRR22显著上调,并独立预测了较短的无进展生存期.
- PRR22显示了与TGF-β信号传递,免疫逃避 (LAG3),微卫星不稳定性 (MSI) 和茎结合的新兴关联.
- 高PRR22表达与对多种药物的耐药性相关,包括双胺和伏利诺斯塔特.
结论:
- 在PRAD中过度表达PRR22与预后不佳,免疫调节和耐药性有关.
- PRR22代表了PRAD的潜在预后生物标志物和治疗标.
- 为了在PRAD中对PRR22进行临床验证和机制性探索,需要进一步的研究.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K